Although people with CKD-alb and CKD-eGFR <60 were more likely to be on insulin and RAAS agents than people with non-CKD, only the 80% on RAAS agents approached Canadian Diabetes Association CPG guidelines recommending their use in those with CKD [14]. This evidence concerns the gene INS and chronic kidney disease.